Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 1 to 25 of 2003

TitleReference numberPublishedLast updated
Digital platforms to support cardiac rehabilitation: early value assessmentHTE35
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphomaTA1113
Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatmentsTA1114
Child maltreatment: when to suspect maltreatment in under 18sCG89
Suspected sepsis in pregnant or recently pregnant people: recognition, diagnosis and early managementNG255
Suspected sepsis in people aged 16 or over: recognition, assessment and early managementNG253
Suspected sepsis in under 16s: recognition, diagnosis and early managementNG254
Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancerTA1110
Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal)TA1112
Nintedanib for treating fibrosing interstitial lung disease in people 6 to 17 years (terminated appraisal)TA1111
Intrapartum careNG235
Low-energy contact X-ray brachytherapy for rectal cancerIPG809
Fetal monitoring in labourNG229
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancerTA1109
Cabotegravir for preventing HIV-1 in adults and young peopleTA1106
Delgocitinib for treating moderate to severe chronic hand eczemaTA1107
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancerTA1108
Iptacopan for treating complement 3 glomerulopathy (terminated appraisal)TA1102
VA ECMO for severe acute heart failure in adultsIPG807
VA ECMO for extracorporeal cardiopulmonary resuscitation (ECPR) in adults with refractory cardiac arrestIPG808
Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal)TA1105
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal)TA1104
Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitorTA1103
Rehabilitation for chronic neurological disorders including acquired brain injuryNG252
Artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures: early value assessmentHTE34

Results per page

  1. 10
  2. 25
  3. 50
  4. All